Does orphan drug legislation really answer the needs of patients?
- 20 June 2008
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 371 (9629), 2041-2044
- https://doi.org/10.1016/s0140-6736(08)60873-9
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Creation and Development of the Public Service Orphan Drug Human Botulism Immune GlobulinPediatrics, 2007
- The genetic tyrosinemiasAmerican Journal Of Medical Genetics Part C-Seminars In Medical Genetics, 2006
- Orphan Drug Designation and PharmacogenomicsBioDrugs, 2006
- Potential Interactions of the Orphan Drug Act and Pharmacogenomics: A Flood of Orphan Drugs and Abuses?American Journal of Law & Medicine, 2005
- The Orphan Drug BacklashScientific American, 2003
- Cures for the Third World's problemsEMBO Reports, 2002
- Orphan products—pain relief for clinical development headachesNature Biotechnology, 2002
- ADA Deficiency TreatmentScience, 1989
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987
- "Orphan Drugs" for the Third WorldAnnals of Internal Medicine, 1981